Akums Drugs and Pharmaceuticals Limited (NSE:AKUMS)
India · Delayed Price · Currency is INR 702.05
+43.85 (6.66%)
Jul 10, 2026, 3:49 PM IST
NSE:AKUMS Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 43,590 | 41,182 | 41,782 | 36,548 | 36,719 |
Other Revenue | 23.9 | 27.79 | 34.8 | 23.7 | 33.29 |
| 43,614 | 41,209 | 41,817 | 36,572 | 36,752 | |
Revenue Growth (YoY) | 5.83% | -1.45% | 14.34% | -0.49% | 34.81% |
Cost of Revenue | 25,897 | 24,993 | 26,204 | 23,493 | 24,145 |
Gross Profit | 17,717 | 16,216 | 15,613 | 13,079 | 12,607 |
Selling, General & Admin | 7,921 | 7,573 | 6,918 | 6,291 | 5,399 |
Other Operating Expenses | 4,550 | 4,008 | 3,848 | 3,765 | 3,104 |
Operating Expenses | 14,016 | 13,115 | 12,023 | 11,184 | 9,449 |
Operating Income | 3,701 | 3,101 | 3,590 | 1,895 | 3,158 |
Interest Expense | -886.22 | -304.07 | -502.51 | -459.73 | -163.38 |
Interest & Investment Income | 1,097 | 249.86 | 119.99 | 78.8 | 46.31 |
Earnings From Equity Investments | - | - | - | -2.03 | 2.03 |
Currency Exchange Gain (Loss) | 79.82 | 44.82 | 72.05 | -38.93 | 26.46 |
Other Non Operating Income (Expenses) | -7.88 | 77.26 | -3,526 | 490.16 | -4,883 |
EBT Excluding Unusual Items | 3,983 | 3,169 | -246.18 | 1,963 | -1,813 |
Impairment of Goodwill | - | - | - | - | -129.77 |
Gain (Loss) on Sale of Assets | -0.55 | -1.12 | -3.17 | 45.75 | -20.66 |
Asset Writedown | 0.63 | 38.27 | 1.38 | -722.64 | 10.55 |
Other Unusual Items | -162.18 | 79.54 | -204.81 | 216.81 | 21 |
Pretax Income | 3,821 | 3,453 | -452.78 | 1,503 | -1,932 |
Income Tax Expense | 1,257 | 14.76 | -460.68 | 524.8 | 576.77 |
Earnings From Continuing Operations | 2,564 | 3,438 | 7.9 | 978.17 | -2,509 |
Minority Interest in Earnings | -12.09 | -56.01 | -48.25 | -29.62 | -16.62 |
Net Income | 2,552 | 3,382 | -40.35 | 948.55 | -2,525 |
Net Income to Common | 2,552 | 3,382 | -40.35 | 948.55 | -2,525 |
Net Income Growth | -24.54% | - | - | - | - |
Shares Outstanding (Basic) | 153 | 150 | 143 | 143 | 143 |
Shares Outstanding (Diluted) | 153 | 150 | 143 | 143 | 143 |
Shares Change (YoY) | 2.33% | 4.58% | - | - | - |
EPS (Basic) | 16.67 | 22.60 | -0.28 | 6.63 | -17.65 |
EPS (Diluted) | 16.67 | 22.60 | -0.28 | 6.63 | -17.65 |
EPS Growth | -26.26% | - | - | - | - |
Free Cash Flow | 9,507 | 1,929 | 1,869 | -1,522 | -2,257 |
Free Cash Flow Per Share | 62.09 | 12.89 | 13.06 | -10.64 | -15.78 |
Dividend Per Share | 1.000 | - | - | - | - |
Gross Margin | 40.62% | 39.35% | 37.34% | 35.76% | 34.30% |
Operating Margin | 8.48% | 7.52% | 8.59% | 5.18% | 8.59% |
Profit Margin | 5.85% | 8.21% | -0.10% | 2.59% | -6.87% |
Free Cash Flow Margin | 21.80% | 4.68% | 4.47% | -4.16% | -6.14% |
EBITDA | 5,105 | 4,484 | 4,733 | 2,908 | 4,005 |
EBITDA Margin | 11.71% | 10.88% | 11.32% | 7.95% | 10.90% |
D&A For EBITDA | 1,405 | 1,383 | 1,142 | 1,013 | 846.75 |
EBIT | 3,701 | 3,101 | 3,590 | 1,895 | 3,158 |
EBIT Margin | 8.48% | 7.52% | 8.59% | 5.18% | 8.59% |
Effective Tax Rate | 32.90% | 0.43% | - | 34.92% | - |
Revenue as Reported | 44,877 | 41,703 | 42,122 | 37,009 | 36,945 |
Advertising Expenses | 368.74 | 394.17 | 389.87 | 354.65 | 294.51 |